SCHEMBL3608511

SCHEMBL3608511

Cc1nnc(F)c(-c2c(F)cc(F)cc2F)c1-c1cccs1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.35
KDM4E B2RXH2 8/20 0.34
GAA P10253 3/20 0.34
MEN1 O00255 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
KMT2A Q03164 1/20 0.34
RAB9A P51151 7/20 0.34
SMN1; SMN2 Q16637 7/20 0.34
NPC1 O15118 4/20 0.34
ALDH1A1 P00352 6/20 0.33
USP2 O75604 1/20 0.33
ALOX15 P16050 1/20 0.33
CASP1 P29466 1/20 0.33
HSD17B10 Q99714 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
NFKB1 P19838 1/20 0.33
NFKB2 Q00653 1/20 0.33
RELA Q04206 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3610666 0.93 MAPT (0.37) MAPTKDM4EGAAMEN1CYP1A2
SCHEMBL3618362 0.86 KDM4E (0.36) MAPTKDM4EGAAMEN1CYP1A2
SCHEMBL3618629 0.84 RPS6KB2 (0.36) MAPTKDM4EGAAMEN1CYP1A2
SCHEMBL4009765 0.78 KCNQ3 (0.34) KDM4EGAAMEN1CYP1A2CYP2C9
SCHEMBL3617725 0.76 TYMP (0.39) MAPTKDM4EGAAMEN1KMT2A
SCHEMBL3611240 0.75 NPC1 (0.38) MAPTKDM4EGAAMEN1CYP1A2
SCHEMBL3311229 0.73 RAPGEF4 (0.35) MEN1KMT2ARAB9ASMN1; SMN2NPC1
SCHEMBL3313721 0.72 RAB9A (0.37) MAPTMEN1KMT2ARAB9ASMN1; SMN2
SCHEMBL3334563 0.70 IKBKB (0.40) CYP1A2CYP2C9CYP2C19SMN1; SMN2ALDH1A1
SCHEMBL4582844 0.69 HSD11B1 (0.41) MAPTKDM4EGAAMEN1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100113464-A1 NOVEL PYRIDAZINE DERIVATIVES SYNGENTA CROP PROTECTION, INC. (US) 2010-05-06 US claimed
EP-2041113-A1 NOVEL PYRIDAZINE DERIVATIVES Syngeta Participations AG (CH) 2009-04-01 EP claimed
WO-2008009406-A1 NOVEL PYRIDAZINE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2008-01-24 WO claimed
US-20100113464-A1 NOVEL PYRIDAZINE DERIVATIVES SYNGENTA CROP PROTECTION, INC. (US) 2010-05-06 US disclosed
EP-2041113-A1 NOVEL PYRIDAZINE DERIVATIVES Syngeta Participations AG (CH) 2009-04-01 EP disclosed
WO-2008009406-A1 NOVEL PYRIDAZINE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113464-A1 NOVEL PYRIDAZINE DERIVATIVES C3AR1, CBR3, C5 MAPT 4832/4885KDM4E 2526/4885GAA 3615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.